Hester Biosciences Ltd

As of November 24, 2025, Hester Bios is in a strong bearish trend, indicated by bearish MACD readings, moving averages, and KST across multiple time frames, despite a mildly bullish signal from Dow Theory on the weekly chart.

Hester Biosciences' latest results show a net profit increase of 76.22% to ₹14.45 crores, largely due to extraordinary income, but net sales declined by 15.20%, indicating operational challenges and concerns about the sustainability of earnings. Overall, while profitability metrics improved, significant revenue drops and margin pressures suggest underlying issues in the business.

Hester Bios has shown steady growth in net sales and profitability, with net sales increasing from INR 178.07 crore in March 2019 to INR 311.10 crore in March 2025, and profit after tax rising from INR 16.56 crore to INR 24.73 crore in the same period, despite some fluctuations in expenses and cash flow. Total assets and liabilities decreased slightly, while cash flow from operating activities improved significantly.

As of 12-Nov, Hester Biosciences Ltd is currently priced at Rs 1,698.00, reflecting a recent increase but facing long-term performance challenges with a year-to-date decline of 29.03%. Despite strong short-term gains and positive financial results, concerns about high debt and low return on capital employed persist, leading to cautious investor sentiment.

As of 30-Oct, Hester Biosciences Ltd's stock price is declining at 1,599.60, down 1.09%, and has underperformed its sector and the Sensex significantly. Despite strong net profit growth, concerns over debt and weak long-term growth prospects contribute to negative investor sentiment.

As of 13-Oct, Hester Biosciences Ltd's stock price is 1,699.90, down 2.34% and underperforming with a total decline of 3.58% over the last two days. Despite reporting a significant net profit growth, concerns over high debt and poor long-term growth have negatively affected investor sentiment, leading to a year-to-date return down 28.95%.

As of 06-Oct, Hester Biosciences Ltd's stock price is 1,800.00, down 1.35%, and has declined for 13 consecutive days, resulting in a total return drop of 12.71%. Despite strong net profit growth, the company faces high debt levels and poor long-term growth prospects, contributing to investor concerns and significant underperformance compared to market benchmarks.

As of October 1, 2025, the market trend has shifted to mildly bearish, indicated by bearish signals from the weekly MACD and Bollinger Bands, despite some mixed signals from the KST and daily moving averages.

Hester Bios has shown mixed historical performance, with net sales increasing from 266.09 Cr in March 2023 to 311.10 Cr in March 2025, while operating profit slightly declined to 64.97 Cr due to rising expenditures. Profit after tax rose to 24.73 Cr in March 2025, and cash flow from operating activities improved significantly to 64.00 Cr, despite a net cash outflow of -6.00 Cr.

As of 24-Sep, Hester Biosciences Ltd is priced at 1,959.00, down 0.71% and has underperformed with a 5% decline over the last six days. Despite recent negative performance, the company shows strong financial fundamentals, including a 145.1% net profit growth, which may support future recovery.

As of 23-Sep, Hester Biosciences Ltd's stock price is declining at 1,973.00, down 0.53%, with a 4.32% drop over the past week. Despite strong financial performance and increased investor interest, the stock has underperformed compared to the benchmark Sensex.

As of 22-Sep, Hester Biosciences Ltd's stock price is 2,008.00, showing a slight increase but underperforming with a -2.29% decline over the past week. Despite strong net profit growth and positive quarterly results, the stock's recent performance and declining investor participation suggest a cautious outlook.